PNC Financial Services Group
CRNX icon

PNC Financial Services Group’s Crinetics Pharmaceuticals CRNX Stock Holding History

PNC Financial Services Group’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$238K Buy
6,361
+867
+16% +$32.2K ﹤0.01% 2340
2026
Q1 		$200K Buy
5,494
+224
+4% +$10K ﹤0.01% 2316
2025
Q4 		$245K Sell
5,270
-682
-11% -$30.4K ﹤0.01% 2146
2025
Q3 		$248K Buy
5,952
+327
+6% +$10.5K ﹤0.01% 2152
2025
Q2 		$162K Buy
5,625
+2,230
+66% +$68.9K ﹤0.01% 2357
2025
Q1 		$114K Buy
3,395
+688
+25% +$25.7K ﹤0.01% 2576
2024
Q4 		$138K Buy
2,707
+187
+7% +$10.5K ﹤0.01% 2465
2024
Q3 		$129K Buy
2,520
+2,323
+1,179% +$120K ﹤0.01% 2513
2024
Q2 		$8.82K Buy
197
+80
+68% +$3.69K ﹤0.01% 3820
2024
Q1 		$5.48K Buy
117
+111
+1,850% +$4.34K ﹤0.01% 3933
2023
Q4 		$213 Buy
+6
New +$184 ﹤0.01% 4486

Other funds holding CRNX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Impax Asset Management Group
Impax Asset Management Group London, United Kingdom $15.4B AUM 26.43% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Universal-Beteiligungs- und Servicegesellschaft
Universal-Beteiligungs- und Servicegesellschaft Frankfurt Am Main, Germany $65.4B AUM 39.83% 1-Year Est. Return

PNC Financial Services Group's CRNX Position: Q2 2026 in Review

PNC Financial Services Group increased its Crinetics Pharmaceuticals (CRNX) stake by 16% in Q2 2026, buying an estimated $32.2K and bringing the position to 6,361 shares worth $238K. The position accounts for ﹤0.01% of the portfolio, ranked #2340.

PNC Financial Services Group first reported a position in CRNX in Q4 2023 and has held it in 11 quarters since. The position peaked at $248K in Q3 2025. 124 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • PNC Financial Services Group held 6,361 shares of Crinetics Pharmaceuticals worth $238K as of Q2 2026.
  • PNC Financial Services Group bought 867 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $32.2K.
  • Crinetics Pharmaceuticals made up ﹤0.01% of PNC Financial Services Group's portfolio in Q2 2026, its #2340 holding.
  • PNC Financial Services Group first reported a position in Crinetics Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
  • PNC Financial Services Group's Crinetics Pharmaceuticals position peaked at $248K in Q3 2025.
  • 124 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on PNC Financial Services Group's 13F filing for Q2 2026, filed 7 Aug 2026.